TY - JOUR
T1 - Electrocardiographic Predictors of Torsadogenic Risk During Dofetilide or Sotalol Initiation
T2 - Utility of a Novel T Wave Analysis Program
AU - Sugrue, Alan
AU - Kremen, Vaclav
AU - Qiang, Bo
AU - Sheldon, Seth H.
AU - DeSimone, Christopher V.
AU - Sapir, Yehu
AU - Striemer, Bryan L.
AU - Brady, Peter
AU - Asirvatham, Samuel J.
AU - Ackerman, Michael J.
AU - Friedman, Paul
AU - Noseworthy, Peter A.
N1 - Publisher Copyright:
© 2015, Springer Science+Business Media New York.
PY - 2015/9/28
Y1 - 2015/9/28
N2 - Introduction: Initiation of class III anti-arrhythmic medications requires telemetric monitoring for ventricular arrhythmias and QT prolongation to reduce the risk of torsades de pointes (TdP). Heart rate-corrected QT interval (QTc) is an indicator of risk, however it is imperfect, and subtle abnormalities of repolarization have been linked with arrhythmogenesis. Purpose: Identification of electrocardiographic predictors of torsadogenic risk through the application of a novel T wave analysis tool. Methods: Among all patients admitted to Mayo Clinic for initiation of dofetilide or sotalol, we identified 13 cases who developed drug-induced TdP and 26 age and sex matched controls that did not develop TdP. The immediate pre-TdP ECG of those with TdP was compared to the last ECG performed prior to hospital discharge in controls using a novel T wave program that quantified subtle changes in T wave morphology. Results: The QTc and 12 T wave parameters successfully distinguished TdP cases from controls. The top performing parameters were the QTc in lead V3 (mean case vs control 480 vs 420 msec, p < 0.001, r = 0.72) and T wave right slope in lead I (mean case vs control −840.29 vs −1668.71 mV/s, p = 0.002, r = 0.45). The addition of T wave right slope to QTc improved prediction accuracy from 79 to 88 %. Conclusion: Our data demonstrate that, in addition to QTc, the T wave right slope is correlated strongly with TdP risk. This suggests that a computer-based repolarization measurement tool that integrates additional data beyond the QTc may identify patients with the greatest torsadogenic potential.
AB - Introduction: Initiation of class III anti-arrhythmic medications requires telemetric monitoring for ventricular arrhythmias and QT prolongation to reduce the risk of torsades de pointes (TdP). Heart rate-corrected QT interval (QTc) is an indicator of risk, however it is imperfect, and subtle abnormalities of repolarization have been linked with arrhythmogenesis. Purpose: Identification of electrocardiographic predictors of torsadogenic risk through the application of a novel T wave analysis tool. Methods: Among all patients admitted to Mayo Clinic for initiation of dofetilide or sotalol, we identified 13 cases who developed drug-induced TdP and 26 age and sex matched controls that did not develop TdP. The immediate pre-TdP ECG of those with TdP was compared to the last ECG performed prior to hospital discharge in controls using a novel T wave program that quantified subtle changes in T wave morphology. Results: The QTc and 12 T wave parameters successfully distinguished TdP cases from controls. The top performing parameters were the QTc in lead V3 (mean case vs control 480 vs 420 msec, p < 0.001, r = 0.72) and T wave right slope in lead I (mean case vs control −840.29 vs −1668.71 mV/s, p = 0.002, r = 0.45). The addition of T wave right slope to QTc improved prediction accuracy from 79 to 88 %. Conclusion: Our data demonstrate that, in addition to QTc, the T wave right slope is correlated strongly with TdP risk. This suggests that a computer-based repolarization measurement tool that integrates additional data beyond the QTc may identify patients with the greatest torsadogenic potential.
KW - Class III antiarrhythmics
KW - Electrocardiography
KW - Risk stratification
KW - T wave analysis
KW - Torsade de pointes
UR - http://www.scopus.com/inward/record.url?scp=84946497980&partnerID=8YFLogxK
U2 - 10.1007/s10557-015-6619-0
DO - 10.1007/s10557-015-6619-0
M3 - Article
C2 - 26411977
AN - SCOPUS:84946497980
SN - 0920-3206
VL - 29
SP - 433
EP - 441
JO - Cardiovascular Drugs and Therapy
JF - Cardiovascular Drugs and Therapy
IS - 5
ER -